The Economic Times
English EditionEnglish Editionहिन्दी
| E-Paper
Search
+

    India set to get a 100 million doses' boost in its Covid fight

    ET Online|
    From Russia with love
    1/5

    From Russia with love

    Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund has tied up with India's Dr. Reddy’s Laboratories to conduct the clinical trials and distribution of Sputnik V vaccine in India. As per the agreement RDIF will supply 100 million doses of the Covid-19 vaccine to Dr. Reddy’s.

    AFP
    Happy news by Nov?
    2/5

    Happy news by Nov?

    The tie-up may also help India get the vaccine sooner than expected. According to RDIF's CEO Kirill Dmitriev, if the trials succeed the vaccines will be available in India as early as November this year.

    AFP
    A promising vaccine
    3/5

    A promising vaccine

    According to G V Prasad, CEO Dr Reddy's, the Sputnik V vaccine has shown promising results in Phase I and II trials. RDIF has also claimed that the vaccine has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences. The Lancet journal had also said that the Sputnik V has been shown to elicit antibody response with no serious adverse events in small human trials.

    Getty Images
    Who's making it?
    4/5

    Who's making it?

    Apart from Dr Reddy's, RDIF is also in talks with four other Indian manufacturers who will be producing these vaccines for India. However, RDIF has refused to reveal the names of the companies.

    Sorely needed
    5/5

    Sorely needed

    The development has come amid an alarming rise in Covid 19 cases in India. The country is now adding almost 1 lakh cases every day and has now crossed the grim 5 mn mark to become the second most affected country in the world. With no peak or plateau in sight, vaccines now seem to be India's only hope in the fight against coronavirus.

    AP
    The Economic Times
    X
    User